



VisionSearch
Bio

SIMULATION-DRIVEN ONCOLOGY

MilanoQ

A simulation-validated therapeutic platform for resistant cancers

Immune-compatible · mutation-targeted · built from safe, natural compounds

Validated across 30+ advanced in-silico simulations

Investor & Partner White Paper

arash@visionsearch.ai · visionsearch.ai


Confidential · 2026

EXECUTIVE SUMMARY

The efficacy of chemotherapy, without the toxicity.

MilanoQ is a next-generation, immune-compatible, mutation-targeted therapeutic system designed to treat resistant cancers — beginning with colorectal cancer driven by NRAS/KRAS Q61H mutations. It is built entirely from safe, natural compounds and has been validated across more than 30 advanced simulations spanning quantum pharmacology, immune-system mapping, and whole-body microdosing. To our knowledge, MilanoQ is one of the most deeply modeled non-toxic oncology platforms in preclinical development.

The results below are **computationally validated in silico**. They represent a strong, internally consistent modeling package that de-risks the biology ahead of wet-lab work — not clinical outcomes. VisionSearch Bio is now raising to convert these simulations into CRO-led preclinical evidence and IND-enabling studies.



THE PROBLEM & THE MARKET

Resistant cancers outrun today's medicine.

Current treatments for advanced, mutation-driven cancers offer poor durability, high toxicity, and frequent relapse. Conventional chemotherapies such as FOLFOX and FOLFIRI suppress the immune system, cause severe organ stress, and fail to prevent long-term resistance or recurrence. Patients are left with a stark trade-off between efficacy and quality of life.

The opportunity is large and underserved. The global colorectal cancer market is estimated at roughly **\$13.7 billion in 2025**, with colorectal cancer drug sales projected to approach **\$20 billion by 2033**. KRAS mutations appear in roughly **40% of colorectal cancers** and NRAS in a further 1–6%. Yet the recent wave of approved KRAS inhibitors — sotorasib (approved for colorectal use in January 2025) and adagrasib — target only the **G12C** variant. The **Q61H** mutations MilanoQ is designed for remain largely unaddressed, leaving a clear clinical and commercial white space.

THE MILANOQ PLATFORM

A four-step mechanism, designed to work with the body.

- 01 — Target** Engages resistant driver mutations (NRAS/KRAS Q61H) directly, rather than relying on broad cytotoxicity.
- 02 — Induce** Drives programmed tumor-cell death (apoptosis) at an IC50 of ~11.5 μ M in modeling.
- 03 — Reactivate** Restores CD8+ T-cell activity ~4.1x — immune engagement normally reserved for biologics and checkpoint inhibitors.
- 04 — Protect** Suppresses mutation escape (<4%) to deliver durable, long-term disease control.

SIMULATION-VALIDATED RESULTS

What the models show.

The following endpoints were produced by MilanoQ's in-silico validation stack. Each is a computational result intended to guide and de-risk subsequent laboratory confirmation.

Endpoint	Result (in silico)	Interpretation
Tumor apoptosis (IC50)	~11.5 μ M	Potent induction of programmed tumor-cell death
CD8+ immune reactivation	~4.1x	Strong cytotoxic T-cell re-engagement
Long-term non-relapse rate	~72%	Durable control across modeled follow-up
Mutation-escape suppression	<4%	Low probability of resistance emergence
Chronic-use safety	180 days	No modeled toxicity over extended dosing
Oral bioavailability	~87%	Enteric-coated delivery simulation

Note — all figures are computationally derived. Wet-lab and preclinical confirmation are the immediate next milestones.

TECHNOLOGY STACK

An unprecedented in-silico validation engine.

Quantum binding simulations

Molecular binding modeled with Qiskit + PennyLane for pre-synthesis precision.

MOISL — immune ecosystem

Models how the therapy reshapes the tumor-immune microenvironment.

TEHM — exhaustion horizon

T-cell exhaustion modeling to predict durability of immune response.

WB-MEM — microdosing map

Whole-body map projecting distribution and exposure across tissues.

Virtual clinical trial

1,000-avatar simulated cohort stress-testing response and variability.

3D organoid + delivery

Tumor-organoid modeling plus enteric-coated delivery (~87% bioavailability).

PIPELINE

One platform. Many resistant tumors.

Indication	Biology	Stage
Colorectal cancer	KRAS / NRAS Q61H — lead indication	Lead / modeled
Lung adenocarcinoma	KRAS+	Evaluation
Multiple myeloma	Hematologic	Evaluation
Glioblastoma · DIPG	CNS / pediatric brain tumor	Exploratory
Pancreatic · Melanoma	Solid tumors	Exploratory
TNBC · NSCLC	Breast / lung	Exploratory

WHY THIS MATTERS

The strengths of three modalities, in one.

Attribute	Chemotherapy	Checkpoint / biologics	MilanoQ
Tumor-killing efficacy	High	Variable	Chemo-comparable
Systemic toxicity	Severe	Moderate	Non-toxic (natural)
Immune activation	Suppresses	Strong	~4.1× CD8+
Resistant-mutation reach	Limited	Limited	Multi-tumor
Combination-ready	Limited	Yes	DCV / checkpoint combo

NEXT STEPS & THE ASK

From simulation to preclinical evidence.

MilanoQ is entering partner conversations and seed-stage investment to advance toward IND-enabling studies. Near-term priorities:

- **CRO-led preclinical validation** — converting the in-silico package into wet-lab and in-vivo evidence.
- **DCV integration strategy** — dendritic-cell-vaccine and immune-checkpoint combination pathways.

- **Seed-stage investment** — to fund IND-enabling studies and build the founding scientific team.

Explore a partnership or investment

arash@visionsearch.ai · visionsearch.ai

Important notice. This document is confidential and provided for information only. It does not constitute an offer to sell or a solicitation of an offer to buy any security. All efficacy, safety, and pharmacokinetic figures herein are derived from computational simulations and have not been evaluated in laboratory, animal, or human clinical studies. Forward-looking statements are subject to significant scientific, regulatory, and commercial risk.